XGN

Exagen Inc.

Price

$7.40

return (12m)

-24.02%

p/e

-9.70

p/bv

15.02

DIVIDEND YIELD

0.00%

XGN price

Exagen

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment XGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

59.83%

3 months

48.59%

1 year

-24.02%

2 years

156.06%

5 years

-47.96%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals XGN

Valuation

P/E

-9.70

Sector -4.26

Industry -4.26

P/BV

15.02

Sector 2.11

Industry 2.11

P/Revenue (PSR)

2.58

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

3.53

Sector 1.25

Industry 1.25

P/Net Current Assets

58.47

Sector -5.47

Industry -5.47

P/Working Capital

6.24

Sector -1.10

Industry -1.10

EPS

-0.79

Sector -1.94

Industry -1.94

BVPS

0.51

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

58.65%

Sector 38.90%

Industry 38.90%

EBITDA Margin

0.00%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

0.00%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

-18.56%

Sector -36.74%

Industry -36.74%

Net Profit Margins

-26.62%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.38

Sector 0.03

Industry 0.03

Profitability

ROE

-154.91%

Sector -61.50%

Industry -61.50%

ROA

-36.45%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

3.18

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

1.83

Sector -0.60

Industry -0.60

Gross Debt / Equity

1.83

Sector -0.83

Industry -0.83

Equity/Assets

0.24

Sector 0.43

Industry 0.43

Liabilities/Assets

0.76

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

8.05%

Sector -

Industry -

5Y Earnings CAGR

-6.75%

Sector -

Industry -

Fundamentals XGN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
XGN Exagen Inc.	$7.40	-22.51%	0.00%	-9.70	15.02	-154.91%	-26.62%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

XGN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Exagen

Exagen Inc.

Average Investor10 user rating

4.0 (1 people)

United States

24 years

Founded: 2002

2019

Time since IPO - 7 years

183

Employees

Exagen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $183.60 million, with shareholders equity totaling $12.22 million.

The company employs approximately 183 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Exagen Inc. reported $71.12 million in revenue, generating net income of $-18.93 million.

Key financial metrics include a P/E ratio of -9.70, a price-to-book (P/B) ratio of 15.02, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker XGN.

Market cap

$183.60 million

Net worth

$12.22 million

$12,220,000.00

Assets

$51.94 million

$51,940,000.00

Total Shares Outstanding

24.00 million

24,000,000

Average Daily Trading Volume

$328.47 Thousand

$328,471.22

Sector

Health Care

Industry

Biotechnology

XGN

XGN revenue and profits

Financial Results XGN

DRAG THE FRAME TO SEE MORE DATA

XGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Exagen (XGN) today?

A cotação de Exagen (XGN) hoje está em US$ 7.40, com uma variação de -24.02% em relação ao último ano. A cotação de Exagen (XGN) iniciou o ano negociando na casa dos US$ 6.08 e hoje está em US$ 7.40. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Exagen (XGN) e dados de ações do Ibovespa e mercados internacionais.

Quando Exagen (XGN) paga dividendos?

Exagen (XGN) não distribuiu dividendos no último ano.

Is Exagen (XGN) a good investment?

Atualmente, Exagen (XGN) está cotada a US$ 7.40, com um P/L de -9.70, representando um desvio de -488% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -24.02 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -24.02%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Exagen (XGN) stock?

Investir em ações de Exagen (XGN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Exagen (XGN) yield today?

A rentabilidade de Exagen (XGN) foi de 59.83% no último mês, -24.02% no último ano e -47.96% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Exagen (XGN) hoje, o investimento total seria de US$ 740.00, com base na cotação atual de US$ 7.40.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 562.25
Em 5 anos: US$ 385.10
Em 10 anos: US$ 740.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

XGN

Exagen Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment XGN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING XGN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Exagen

Exagen Inc.

United States

24 years

2019

183

PROFIT X PRICE XGN

Financial Results XGN

XGN cash flow

Asset, Revenue and Profit Growth - XGN

XGN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions